REGN9933 + REGN7508

**REGN9933 + REGN7508** is an experimental combination of two monoclonal antibodies developed by Regeneron for anticoagulation and prevention of venous thromboembolism (VTE), particularly in settings such as total knee arthroplasty, atrial fibrillation, and peripherally inserted central catheters (PICC)[1][2][5][6]. Both agents target distinct domains of the coagulation protein Factor XI—REGN7508 binds the catalytic domain to maximize anticoagulant activity while minimizing bleeding risk, and REGN9933 binds the A2 domain to provide options for patients at highest bleeding risk[1][2]. By inhibiting Factor XI, the antibodies aim to prevent the formation of pathological blood clots with a reduced risk of bleeding compared to standard anticoagulants[1][3][5][7]. Clinical studies have shown robust antithrombotic effects for each antibody with a favorable safety profile, with trials indicating efficacy in prevention of VTE and low rates of clinically relevant bleeding when administered as intravenous single doses after surgery[1][3][6][8].

Other names

REGN9933REGN-9933REGN 9933REGN7508REGN-7508REGN 7508